This Medudy course is a video podcast for physicians on the SINGLE-AF study, which was presented as a hot-line/late-breaking clinical trial at the 2026 ESC Congress in Munich and published simultaneously in the New England Journal of Medicine. Prof. Dr. Christian-Hendrik Heeger and Prof. Dr. Julian Chun discuss the first randomized trial on direct oral anticoagulation (DOAC) in patients with atrial fibrillation and intermediate stroke risk (CHA2DS2-VASc score of 1 for men and 2 for women).
They describe the design of the prospective, multicenter Korean study involving 1,803 patients who were randomized 1:1 to receive apixaban or rivaroxaban versus no anticoagulation, as well as the primary outcome at two years: a significant reduction in the combined primary endpoint of stroke, systemic embolism, major bleeding, or cardiovascular death from 1.5% to 0.5%, driven primarily by fewer strokes and without an increase in major bleeding. The experts take a critical look at the low absolute event rates, the use of aspirin in the control group, and the generalizability of an East Asian cohort to Western European patients. Furthermore, they translate the results into everyday clinical practice: How should one advise the typical patient with only one risk factor? How do the data fit into the current Class IIa recommendation? What roles do catheter ablation and AF burden play? And when can oral anticoagulation be reevaluated following successful ablation?
Note: All “speakers” appearing in Medudy videos are AI-based avatars used to enhance the educational experience. The individuals on whom the avatars are based have expressly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by Medudy’s medical team.
Upon completion of this course, you will know:
- the design, patient population, and endpoints of the SINGLE-AF study in patients with atrial fibrillation and intermediate stroke risk (CHA2DS2-VASc score of 1 for men and 2 for women).
- the key results regarding the composite primary endpoint of stroke, systemic embolism, major bleeding, or cardiovascular death among patients receiving DOAC therapy versus those not receiving anticoagulation.
- the safety data from the study and why the reduction in thromboembolic events was not offset by an increase in severe bleeding.
- the study's limitations, including the low number of events, the use of aspirin in the control group, and the generalizability of an East Asian cohort to Western European practice.
- how the results fit into the current Class IIa recommendation on anticoagulation for patients at intermediate risk of stroke, and what they might mean for future guidelines.
- Practical strategies for individualized decision-making, including the role of catheter ablation, AF burden, and reassessment of oral anticoagulation following successful ablation.
